B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS

Ítems similars

• B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS
  per: P. Musto, et al.
  Publicat: (2023-05-01)
• Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients
  per: Niels W. C. J. van de Donk, et al.
  Publicat: (2026-06-01)
• P366: BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED PRECURSOR B-ALL IN ADULTS. A PHASE II HOVON TRIAL
  per: A. Rijneveld, et al.
  Publicat: (2022-06-01)
• P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
  per: K. Groen, et al.
  Publicat: (2022-06-01)
• P10 | HIGH ACCURACY OF NEXT-GENERATION FLOW IN PREDICTING MEASURABLE RESIDUAL DISEASE BY NEXT-GENERATION SEQUENCING IN THE 10⁻⁶ RANGE: A PROSPECTIVE COMPARISON WITHIN THE PHASE III EMN24 ISKIA TRIAL
  per: M. D'Agostino, et al.
  Publicat: (2026-04-01)